TScan Therapeutics, Inc. (NASDAQ:TCRX – Get Rating) – Investment analysts at HC Wainwright dropped their Q1 2023 earnings per share estimates for TScan Therapeutics in a research report issued to clients and investors on Thursday, March 9th. HC Wainwright analyst A. Fein now forecasts that the company will post earnings per share of ($0.80) for the quarter, down from their prior forecast of ($0.71). HC Wainwright has a “Buy” rating and a $15.00 price objective on the stock. The consensus estimate for TScan Therapeutics’ current full-year earnings is ($3.12) per share. HC Wainwright also issued estimates for TScan Therapeutics’ Q2 2023 earnings at ($0.82) EPS, Q3 2023 earnings at ($0.84) EPS, Q4 2023 earnings at ($0.86) EPS, FY2023 earnings at ($3.32) EPS, FY2024 earnings at ($2.96) EPS, FY2025 earnings at ($2.84) EPS, FY2026 earnings at ($2.73) EPS and FY2027 earnings at ($2.22) EPS.
TScan Therapeutics Stock Down 3.0 %
TScan Therapeutics stock opened at $2.93 on Monday. The stock’s fifty day moving average is $2.32 and its two-hundred day moving average is $2.51. The company has a debt-to-equity ratio of 0.29, a current ratio of 7.17 and a quick ratio of 8.51. TScan Therapeutics has a 1-year low of $1.45 and a 1-year high of $4.56. The stock has a market cap of $70.55 million, a PE ratio of -1.07 and a beta of 0.44.
Institutional Trading of TScan Therapeutics
TScan Therapeutics Company Profile
TScan Therapeutics, Inc, a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors.
- Get a free copy of the StockNews.com research report on TScan Therapeutics (TCRX)
- What the SVB Financial Collapse Means for U.S. Banks
- MarketBeat Week in Review – 3/6 – 3/10
- 2 Offshore Drilling Stocks Set to Extract Big Profits
- Three Staples Stocks With Double-Digit Upside Ahead
- Can Investors Trust Consumers to Lift American Outdoor Brands?
Receive News & Ratings for TScan Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TScan Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.